Ocular Therapeutix’s Promising Developments and Strategic Execution Justify Buy Rating

William Blair analyst Lachlan Hanbury Brown has maintained their bullish stance on OCUL stock, giving a Buy rating on May 19.

Lachlan Hanbury Brown has given his Buy rating due to a combination of factors surrounding Ocular Therapeutix’s promising developments. The company has successfully closed enrollment for its SOL-R study, ensuring a sufficient number of participants to meet its target, which sets the stage for a significant data readout in early 2027. This progress is seen as a positive step towards achieving key milestones in their clinical trials.
Additionally, the anticipated top-line results from the SOL-1 Phase III study, expected in the first quarter of 2026, are considered a major catalyst for the stock. The potential of Ocular’s lead asset, Axpaxli, to significantly advance the treatment of wet AMD, further supports the Buy rating. The strategic planning and execution by the management team, including incorporating buffers in enrollment numbers, add confidence to the company’s ability to meet its objectives.

In another report released on May 19, Bank of America Securities also reiterated a Buy rating on the stock with a $17.00 price target.